Skin toxicity of targeted cancer agents: mechanisms and intervention

Area of Science:

• Oncology
• Dermatology
• Molecular Biology

Background:

• Targeted agents are crucial in managing malignancies by disrupting cancer-specific molecular pathways.
• These therapies affect normal cells, leading to adverse events, particularly dermatologic toxicities.
• The development of novel agents with broader targets necessitates continuous updates in managing side effects.

Purpose of the Study:

• To provide an overview of dermatologic toxicities associated with targeted therapies.
• To discuss the underlying pathomechanisms of these cutaneous adverse events.
• To explore strategies for alleviating skin toxicities based on emerging insights.

Main Methods:

• Review of current literature on targeted agents and their dermatologic side effects.
• Analysis of molecular mechanisms driving both therapeutic efficacy and cutaneous toxicities.
• Synthesis of clinical observations and management strategies for skin adverse events.

Main Results:

• Receptor tyrosine kinase inhibitors and downstream effectors are common culprits for dermatologic toxicities.
• Specific molecular pathways targeted by these agents are implicated in the pathogenesis of skin reactions.
• Effective management strategies are emerging, informed by a deeper understanding of the pathomechanisms.

Conclusions:

• Dermatologic toxicities are significant adverse events associated with targeted cancer therapies.
• Understanding the molecular basis of these toxicities is key to developing effective management and mitigation strategies.
• Continued research into targeted agents and their side effects is essential for improving patient care.